Pharmaceutical Technology

JUNE 12, 2023

The evidence for clinical benefit was “very clear”, said Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School. Leqembi is the second drug developed by Biogen and Eisai for the treatment of Alzheimer’s disease.

Medical Schools 52

Medical Schools Labelling Drug Development 52

European Pharmaceutical Review

SEPTEMBER 2, 2022

She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. US Food and Drug Administration. She holds a MSc in Public Health and a PhD in Biophysics and Molecular Biology. About the author. References. Risk management plan [Internet].

Adverse Reactions 96

Adverse Reactions Documentation Medical Schools Packaging 96

Pharmaceutical Technology

APRIL 24, 2023

In an email to this news service, João Conde, PhD, professor at NOVA Medical School, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59